CLARIFICATION REGARDING DISCLOSURE NOTICES

As previously announced, Moberg Derma is conducting a directed share issue in connection with the company’s acquisition of its U.S. distributor Alterna LLC. In conjunction with subscription of the new shares, delivery will initially take place through a share lending agreement entered into between the issuing agent and Östersjöstiftelsen. As a consequence, and pending registration of the rights issue, Östersjöstiftelsen has temporarily reduced its holding in Moberg Derma and the holding of AP3 (the Third Swedish National Pension Fund) is temporarily exceeding 5 percent of the company's shares and votes. After completion of the share issue, Östersjöstiftelsen will regain the lent shares. Once the share issue is registered, the ownership of AP3 will decrease as a result of the higher number of shares in the company.

For further information, please contact:
Peter Wolpert, President and CEO of Moberg Derma
Telephone: +46 8 522 307 00
Mobile: +46 70-735 71 35
E-mail: peter.wolpert@mobergderma.se

Magnus Persson, IR
Mobile: +46 73-355 26 01
E-mail: magnus.persson@mobergderma.se

About Moberg Derma
Moberg Derma AB (publ), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company’s products are based on proven compounds, which reduce time to market, development costs and risk. Moberg Derma’s first product Nalox™/Emtrix® - for nail disorders - became the Nordic market leader directly after launch in autumn 2010 and international launch is ongoing. The portfolio includes approved and launched products to projects in the preclinical and clinical phase. The share of Moberg Derma is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergderma.com

Tags: